What Medtronic, Inc. Did Wrong: 3 Reasons Renal Denervation Is Not Dead Yet

free biotech news

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Boston Scientific CEO Michael Mahoney has repeated that the medical device giant remains enthusiastic about renal denervation as a treatment for high blood pressure—even after Medtronic and Covidien have decided to pull back from the space.

Hey, check out all the engineering jobs. Post your resume today!

MORE ON THIS TOPIC